57 results
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
11 Mar 19
Results of Operations and Financial Condition
4:12pm
by a deep commitment to people with PWS and their families, and we’ll continue to evaluateZGN-1258, as well as explore other potential options within our … that she has joined the Zafgen team,” said Mr. Hatfield. “We also want to thank Dennis for his many contributions to Zafgen and his commitment
DEFA14A
EX-2.1
LRMR
Larimar Therapeutics Inc
18 Dec 19
Additional proxy soliciting materials
8:11am
, license, or other legally binding commitment or undertaking of any nature to which such Person is a party or by which such Person or any of its assets …
3.14(c)
FDCA
3.14(c)
Funding Commitment
Funding Counterparty
GAAP
3.7(a)
Grant Date
3.6(f)
Holdings
Preamble
Investor Agreements
Liability
Term
Section
8-K
EX-2.1
LRMR
Larimar Therapeutics Inc
18 Dec 19
Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement
8:13am
, license, or other legally binding commitment or undertaking of any nature to which such Person is a party or by which such Person or any of its assets …
3.14(c)
FDCA
3.14(c)
Funding Commitment
Funding Counterparty
GAAP
3.7(a)
Grant Date
3.6(f)
Holdings
Preamble
Investor Agreements
Liability
Term
Section
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
7 Jun 18
Zafgen, Inc. Appoints Industry Veteran and Healthcare Policy Expert Dr. Wendy Everett to its Board of Directors
5:06pm
and representing the interests of our shareholders.”
Mr. Hatfield continued, “We extend our deep appreciation to Bruce and Fran for their commitment
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
12 Oct 17
Zafgen Appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to Continue as President, Appointed Chief Scientific Officer
12:00am
that warrant an increased commitment to advance our understanding of its therapeutic potential and develop new drugs leveraging its impact. The breadth
8-K
EX-99.2
mzr ibnni
8 Dec 20
Regulation FD Disclosure
7:40am
8-K
EX-99.1
dunco5s6
4 Mar 21
Larimar Therapeutics Reports Fourth Quarter and Full Year 2020 Operating and Financial Results
7:30am
8-K
EX-99.2
timbw1edbb5 q59p5p
11 May 21
Other Events
8:34am
8-K
EX-99.1
x7izfbi6r7cxh
25 Mar 22
Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results
7:11am
PRE 14A
lwcx9f
12 Apr 24
Preliminary proxy
6:06am
S-1
EX-10.6
joaa5zja67fi6zfk4x3y
18 Apr 14
IPO registration
12:00am
S-1
EX-10.8
bnp y6subcym
18 Apr 14
IPO registration
12:00am
S-1
EX-10.10
4dha4cc
18 Apr 14
IPO registration
12:00am
8-K
EX-14.1
hg2 kycok
2 Jun 20
Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics
7:49am